Abstract 2285: Menopausal hormone therapy (MHT) use and breast cancer risk by receptor subtypes: results from the New South Wales Cancer Lifestyle and EvAluation of Risk (CLEAR) study

Mapping Intimacies ◽

10.1158/1538-7445.am2017-2285 ◽

2017 ◽

Author(s):

Usha G. Salagame ◽

Emily Banks ◽

Dianne O’Connell ◽

Sam Egger ◽

Karen Canfell

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

New South ◽

New South Wales ◽

Menopausal Hormone Therapy ◽

Receptor Subtypes ◽

South Wales

Download Full-text

Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study

PLoS ONE ◽

10.1371/journal.pone.0205034 ◽

2018 ◽

Vol 13 (11) ◽

pp. e0205034

Author(s):

Usha Salagame ◽

Emily Banks ◽

Dianne L. O’Connell ◽

Sam Egger ◽

Karen Canfell

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

New South ◽

New South Wales ◽

Menopausal Hormone Therapy ◽

Receptor Subtypes ◽

South Wales

Download Full-text

Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study

International Journal of Cancer ◽

10.1002/ijc.29942 ◽

2015 ◽

Vol 138 (8) ◽

pp. 1905-1914 ◽

Cited By ~ 6

Author(s):

Usha Salagame ◽

Emily Banks ◽

Freddy Sitas ◽

Karen Canfell

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

New South ◽

New South Wales ◽

Menopausal Hormone Therapy ◽

South Wales

Download Full-text

Berlin, 09.09.2019 – Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG) zur Lancet-Studie „Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence“ (29. August 2019; doi:10.1016/S0140-6736(19)31709-X)

Geburtshilfe und Frauenheilkunde ◽

10.1055/a-1060-5694 ◽

2019 ◽

Vol 79 (12) ◽

pp. 1259-1260

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Meta Analysis ◽

Menopausal Hormone Therapy ◽

Epidemiological Evidence ◽

Individual Participant

Download Full-text

BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

Post Reproductive Health ◽

10.1177/2053369120983154 ◽

2021 ◽

pp. 205336912098315

Author(s):

Haitham Hamoda ◽

Susan R Davis ◽

Antonio Cano ◽

Edward Morris ◽

Sonia Davison ◽

...

Keyword(s):

Breast Cancer ◽

Risk Assessment ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Menopausal Hormone Therapy ◽

Joint Statement ◽

Pharmacovigilance Risk Assessment Committee ◽

Assessment Committee

Download Full-text

Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG) zur Lancet-Studie „Type and timing of menopausal hormone therapy and breast cancer risk: individual participant metaanalysis of the worldwide epidemiological evidence“ (29. August 2019; doi:10.1016/S0140-6736(19)31709-X)

Senologie - Zeitschrift für Mammadiagnostik und -therapie ◽

10.1055/a-1102-4436 ◽

2021 ◽

Vol 18 (01) ◽

pp. 23-24

Author(s):

Günter Emons ◽

Anton J. Scharl

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Menopausal Hormone Therapy ◽

Epidemiological Evidence ◽

Individual Participant

Download Full-text

Kommentar zur Hormonersatztherapie – Ergänzung zur DGGG-Stellungnahme zur Lancet-Studie „Type and timing of menopausal hormone therapy and breast cancer risk: individual participant metanalysis of the worldwide epidemiological evidence“ (29. August 2019)

Senologie - Zeitschrift für Mammadiagnostik und -therapie ◽

10.1055/a-1342-5058 ◽

2021 ◽

Vol 18 (01) ◽

pp. 25-26

Author(s):

Christian Albring ◽

Georg Döhmen ◽

Ludwig Kiesel ◽

Joseph Neulen ◽

Katrin Schaudig ◽

...

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Menopausal Hormone Therapy ◽

Epidemiological Evidence ◽

Individual Participant

Download Full-text

Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life

European Journal of Epidemiology ◽

10.1007/s10654-018-0431-7 ◽

2018 ◽

Vol 34 (3) ◽

pp. 267-278

Author(s):

Marie Søfteland Sandvei ◽

Lars J. Vatten ◽

Elisabeth Krefting Bjelland ◽

Anne Eskild ◽

Solveig Hofvind ◽

...

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Body Mass ◽

Effect Modification ◽

Menopausal Hormone Therapy ◽

Risk Effect

Download Full-text

Abstract 655: Menopausal hormone therapy and breast cancer risk: The CECILE Study

10.1158/1538-7445.am2012-655 ◽

2012 ◽

Author(s):

Emilie Cordina-Duverger ◽

Thérèse Truong ◽

Antoinette Anger ◽

Claire Mulot ◽

Patrick Arveux ◽

...

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Menopausal Hormone Therapy

Download Full-text

Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort

Cancer Epidemiology Biomarkers & Prevention ◽

10.1158/1055-9965.epi-08-0435 ◽

2008 ◽

Vol 17 (11) ◽

pp. 3150-3160 ◽

Cited By ~ 59

Author(s):

Louise A. Brinton ◽

Douglas Richesson ◽

Michael F. Leitzmann ◽

Gretchen L. Gierach ◽

Arthur Schatzkin ◽

...

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Menopausal Hormone Therapy ◽

Health Study ◽

Study Cohort

Download Full-text

Menopausal hormone therapy and breast cancer risk

Best Practice & Research Clinical Endocrinology & Metabolism ◽

10.1016/j.beem.2021.101577 ◽

2021 ◽

pp. 101577

Author(s):

Serge Rozenberg ◽

Victoria Di Pietrantonio ◽

Jean Vandromme ◽

Christine Gilles

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Therapy ◽

Menopausal Hormone Therapy

Download Full-text